title: Burden of basal cell carcinoma in USA.
abstract: Basal cell carcinoma (BCC) is the most common malignancy diagnosed in the USA and its incidence continues to increase. While BCC is still most prevalent in the older segments of the population, it is becoming ever more frequent in younger individuals. The costs of treatment and morbidity associated with BCCs place a heavy public health and economic burden on patients, their families and the American healthcare system and underscore the importance of efficient management and prevention efforts directed toward this malignancy. In this article, we address economic aspects of BCC using evidence from large-scale epidemiological studies. This information may help clinicians in developing better and more cost-effective methods for dealing with the most common cancer in America and in the world.
authors.affiliation: Department of Dermatology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
authors.forename: Xinyuan
authors.initials: X
authors.lastname: Wu
authors.affiliation: Center for Health Policy & Outcomes, Memorial Sloan Kettering Cancer Center, New York, NY 10017, USA.
authors.forename: Elena E
authors.initials: EE
authors.lastname: Elkin
authors.affiliation: Department of Dermatology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
authors.forename: Ashfaq A
authors.initials: AA
authors.lastname: Marghoob
mesh_terms: D002280:Basal Cell Carcinoma / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D003362:Cost-Benefit Analysis; D017048:Health Care Costs; D006801:Humans; D015994:Incidence; D012878:Skin Neoplasms / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy; D014481:United States / Q000453:epidemiology
keywords: USA; basal cell carcinoma; burden; cost; cost analysis; cost–effectiveness; economics; epidemiology; healthcare; incidence nonmelanoma; medicare; morbidity; population; procedures; registries; skin cancer; skin neoplasms; treatment modality; treatment pattern; trends